Exits

 

Lab21 (May 2014)

(Cambridge, UK) 

Lab21 is a global provider of state-of-the-art diagnostic products and services, supporting healthcare and environmental markets; specializing in personalized diagnostic testing for disease identification, disease predisposition and personalized medicine to protect people from the health problems of tomorrow.

Lab 21 merged with Novacyt a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers.  Read the press release here.

 

Selah Logo

Selah Genomics (April 2014)

Greenville, SC

Selah Genomics specializes in supporting healthcare providers and the pharmaceutical industry with advanced molecular and genomic diagnostic services. UCAN invested in August, 2013.

Selah Genomics was acquired by EKF Diagnostics, a UK-based point-of-care diagnostics firm, in a deal worth more than 10x UCAN’s investment.  Click here for more details.

Verdeeco

Verdeeco (April 2014)

Atlanta, GA Verdeeco provides a Grid-as-a-Service platform that allows power and water utilities to collect, analyze and create value from the massive volumes of data being created by the transition to the smart grid.  UCAN invested in June, 2011.

Verdeeco was acquired by Sensus, a Raleigh-based global leader in utility infrastructure systems and resource conservation. The press release can be found here.

Sabal Medical (January 2011)

Charleston, SC Sabal Medical is a medical technology company specializing in bedside automated medication carts and electronic medical record software integration.  UCAN invested in August, 2010.

Sabal was acquired by Swisslog, a global supplier of integrated logistics solutions, giving UCAN investors a return of more than three times their investment in less than six months. The press release can be found here.

Selah Technologies (December 2009)

Pendleton, SC

Selah Technologies is an advanced materials manufacturing company developing and commercializing two proprietary nanotechnologies. Our mission is to consistently deliver high quality nanomaterials to the global marketplace.  UCAN members invested in April, 2008.

Selah Technologies was acquired by medical diagnostics company Lab 21, Ltd. The press release can be found here.